We joined forces with QIAGEN, another world-class company, to accelerate global CDx access. Our collective expertise allows us to anticipate and understand your specific needs throughout the clinical trial process.
Sysmex Inostics
Developers of one of the most sensitive NGS liquid biopsy tests on the market
Plasma-Safe-Seqs (PSS) designed to leave no molecule behind
10 years of CLIA lab support for breakthroughs in clinical trials
Creators of first commercially available liquid biopsy test, OncoBEAM™
QIAGEN
Unparalleled global CDx development and commercialization capabilities
Over 15 years of developing CDx product with pharmaceutical partners
Strong regulatory capabilities with 10 CDx FDA PMA approvals
Capabilities to register CDx assays globally in all target markets
Clinical trial journey
Our combined areas of expertise allow us to anticipate and understand your various needs throught the clinical trial process.
